The South Park Jinx Could Be Coming for Weight-Loss Stocks

• If tradition holds, South Park’s latest Ozempic storyline could mark a short-term top in shares of obesity drug makers.
• Shares of companies featured prominently in the animated comedy often fall in the following year.  
• “One year after appearing on South Park, the median stock underperforms the S&P 500 by 7%,” Spectra Markets said. 

South Park’s latest gag is aimed at the booming market for weight loss drugs like Ozempic — and the special could continue a long tradition of prominent stocks selling off not long after they’re